

APPENDIX

APPENDIX

Interpreting STD Surveillance Data

Sexually Transmitted Disease Surveillance, 2006 presents surveillance information derived from the official statistics for the reported occurrence of nationally notifiable sexually transmitted diseases in the United States, test positivity and prevalence data from numerous prevalence monitoring initiatives, sentinel surveillance of gonococcal antimicrobial resistance, and national health care services surveys.

Nationally Notifiable STD Surveillance

Nationally notifiable STD surveillance data are collected and compiled from reports sent by the STD control programs and health departments in the 50 states, the District of Columbia, selected cities, U.S. dependencies and possessions, and independent nations in free association with the United States to the Division of STD Prevention (DSTDP), National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention (NCHHSTP), Centers for Disease Control and Prevention (CDC). Included among the dependencies, possessions, and independent nations are Guam, Puerto Rico, and the Virgin Islands. These entities are identified as “outlying areas” of the United States in selected figures and tables.

Reporting Formats

STD morbidity data presented in this report are compiled from a combination of data reported on standardized hardcopy report forms and electronic data received via the National Electronic Telecommunications System for Surveillance (NETSS).

Summary Report Forms (hardcopy format)

The following hardcopy forms were used to report national STD morbidity data:

1. FORM CDC 73.998: *Monthly Surveillance Report of Early Syphilis*. This monthly hardcopy reporting form was used from 1984 to 2002 to report summary data for P&S syphilis and early latent syphilis by county and state.

2. FORM CDC 73.688: *Sexually Transmitted Disease Morbidity Report*. This quarterly hardcopy reporting form was used from 1963 to 2002 to report summary data for all stages of syphilis, congenital syphilis, gonorrhea, chancroid, chlamydia, and other STDs by sex and source of report (private vs. public) for the 50 states, Washington, D.C., and 64 selected cities (including San Juan, Puerto Rico) and outlying areas of the United States. Note: genital chlamydial infection became a nationally notifiable condition in 1996, and the form was modified to support reporting of chlamydia that year. Congenital syphilis was dropped from this aggregate form in 1995 and replaced by the case-specific CDC 73.126 form listed below.

3. FORM CDC 73.2638: *Report of Civilian Cases of Primary & Secondary Syphilis, Gonorrhea, and Chlamydia by Reporting Source, Sex, Race/Ethnicity, and Age Group*. This annual hardcopy form was used from 1981 to 2002 to report summary data for P&S syphilis, gonorrhea, and chlamydia by age, race, sex and source (public vs. private) for all states and seven large cities (Baltimore, Chicago, New York City, Los Angeles, Philadelphia, San

Francisco, and Washington, D.C.), and outlying areas of the United States. Note: genital chlamydial infection became a nationally notifiable condition in 1996 and the form was modified to support reporting of chlamydia that year.

4. FORM CDC 73.126: *Congenital Syphilis (CS) Case Investigation and Report*. This case-specific hardcopy form was first used in 1983 and continues to be used to report detailed case-specific data for congenital syphilis in some reporting areas.

National Electronic Telecommunications System for Surveillance (NETSS, electronic format)

Notifiable STD data reported electronically through NETSS comprise the nationally notifiable disease information that is published in the *Morbidity and Mortality Weekly Report (MMWR)*.

As of December 31, 2003, all 50 states and Washington, D.C. had converted from summary hardcopy reporting to electronic submission of line-listed (i.e., case-specific) STD data via NETSS (41 reporting areas are submitting congenital syphilis surveillance data via NETSS). Puerto Rico converted to electronic reporting in 2006. Guam and the Virgin Islands continue to report using summary hardcopy forms.

Jurisdictions differ in their ability to resolve differences in total cases derived from summary hardcopy monthly, quarterly, and annual reports (as well as electronically submitted line-listed data). Thus, depending on the database used, there may be discrepancies in the total number of cases among the figures and tables for earlier years. In most instances, these discrepancies are less than 5% of total reported cases and have minimal impact on national case totals and rates. However, for a specific jurisdiction, the discrepancies may be larger.

Surveillance data and updates sent to CDC on hardcopy forms and for NETSS electronic data through June 22, 2007 have been included in this report. Data received after this date will appear in subsequent annual Surveillance Reports. The data presented in the figures and tables in this document supersede those in all earlier publications.

Population Denominators and Rate Calculations

2000–2006 Rates and Population

Crude incidence rates (new cases/population) were calculated on an annual basis per 100,000 population. In this report, the 2006 rates for the United States, all states, counties, metropolitan statistical areas (MSAs), and outlying areas were calculated by dividing the number of cases reported from each area in 2006 by the estimated area-specific 2005 population (the most current detailed population file available at time of publication).

The National Center for Health Statistics released bridged race population counts for 2000–2005 resident population based on the Census 2000 counts. These estimates resulted from bridging the 31 race categories used in Census 2000, as specified in the 1997 Office of Management and Budget (OMB) standards, to the five race/ethnicity groups specified under the 1977 OMB standards.

From 2001 to 2002, population estimates for Guam were obtained from the Guam Bureau of Statistics and Plans; estimates for Puerto Rico were obtained from the Bureau of Census; and estimates for the Virgin Islands were obtained from the University of the Virgin Islands. After 2002, population estimates for all outlying areas were obtained from the Bureau of Census web site <http://www.census.gov/ipc/www/idb/tables.html>. The 2005–2006 rates for

outlying areas were calculated using the 2005 population estimates.

Due to use of the updated population data, rates for the period 2000–2005 may be different from prior *Surveillance Reports*.

1990–1999 Rates and Population

The population counts for 1990–1999 incorporated the bridged single-race estimates of the April 1, 2000 resident population. These files were prepared by the U.S. Census Bureau with support from the National Cancer Institute.

1981–1989 Rates and Population

For the United States, rates were calculated using Bureau of the Census population estimates for 1981 through 1989 (Bureau of the Census; United States Population Estimates by Age, Sex and Race: 1980–1989 [Series P-25, No. 1045]; Washington: U.S. Government Printing Office, 1990; and United States Population Estimates by Age, Sex and Race: 1989 [Series P-25, No. 1057]; Washington: U.S. Government Printing Office, 1990.

1941–1980 Rates and Population

Rates for 1941–1980 are based on population estimates from the Bureau of Census and currently maintained by the Division of STD Prevention.

1941–2006 Congenital Syphilis Rates and Live Births

Congenital syphilis (CS) data in Table 1 of *Sexually Transmitted Disease Surveillance 2006* present the number of congenital syphilis cases per 100,000 live births for all years during the period 1941 through 2006. Previous publications presented congenital syphilis rates per 100,000 population for 1941–1994 and for cases diagnosed at < 1 year of age per 100,000 live births. To allow for trends in CS rates to be compared over time, beginning in 2006

live births will be used as the denominator for CS and case counts will no longer be limited to those diagnosed within the first year of life. CS morbidity (cases) are assigned to their year of birth. Rates of congenital syphilis for 1963–1988 were calculated using published live birth data (NCHS; Vital Statistics Report, United States, 1988 [Vol.1-Natality]). Congenital syphilis rates for 1989–2003 were calculated using live births from the National Center for Health Statistics (NCHS) (Vital Statistics: Natality Tapes 1989–2002 or Vital Statistics Reports, United States 1999, Vol. 48 No.10-Natality). Race-specific rates for 2004–2006 were calculated using live birth data for 2004.

Reporting Practices

Although most areas generally adhere to the national notifiable STD case definitions collaboratively developed by the Council of State and Territorial Epidemiologists (CSTE) and CDC, there may be differences in the policies and systems for collecting surveillance data. Thus, comparisons of case numbers and rates between jurisdictions should be interpreted with caution. However, since case definitions and surveillance activities within a given area remain relatively stable over time, trends should be minimally affected by these differences. In many areas, the reporting from publicly supported institutions (e.g., STD clinics) has been more complete than from other sources (e.g., private practitioners). Thus, trends may not be representative of all segments of the population.

Reporting of Metropolitan Statistical Area-specific Surveillance Data

Sexually Transmitted Disease Surveillance, 2006 continues the presentation of STD incidence data and rates for the fifty Metropolitan Statistical Areas (MSAs) with the largest populations based on 2000 U.S.

Census data. *Sexually Transmitted Disease Surveillance* reports prior to 2005 presented data by selected cities which estimated city-specific morbidity and were derived from county data. Since county data were used to estimate city-specific morbidity and current STD project areas' reporting practices do not support direct identification of city-specific morbidity reports, MSAs (described below) were chosen as a geographic unit smaller than a state or territory for presentation of STD morbidity data.

Metropolitan Statistical Areas are defined by the Office of Management and Budget to provide nationally consistent definitions for collecting, tabulating, and publishing federal statistics for a set of geographic areas.¹ An MSA is associated with at least one urbanized area that has a population of at least 50,000. The MSA comprises the central county or counties containing the core, plus adjacent outlying counties having a high degree of social and economic integration with the central county as measured through commuting. The title of an MSA includes the name of its principal city with the largest Census 2000 population. If there are multiple principal cities, the names of the second largest and third largest principal cities appear in the title in order of descending population size.

The MSA concept has been used as a statistical representation of the social and economic linkages between urban cores and outlying, integrated areas. However, MSAs do not equate to an urban-rural classification; all counties included in MSAs and many other counties contain both urban and rural territory and populations. Programs that treat all parts of an MSA as if they were as urban as the densely settled core ignore the rural conditions that may exist in some parts of the area. In short, MSAs are not designed as a general purpose geographic framework for nonstatistical activities or for use in program funding formulas.

For more information on MSA definitions used in this report, please visit this web site:

<http://www.census.gov/population/estimates/metro-city/03mfips.txt>

Management of Unknown, Missing or Invalid Age Group, Race/Ethnicity, and Sex Data

The percentage of unknown, missing or invalid data for age group, race/ethnicity, and sex varies from year to year, state to state, and by disease for reported STDs (Table A1).

When the percentage of unknown, missing, or invalid data for the variables - age group, race/ethnicity, and sex - exceeds 50% for any state, the state's incidence data and population data are excluded from the tables presenting data stratified by one or more of these variables. For those states reporting > 50% valid data for these variables, unknown, missing or invalid data are redistributed based on the state's distribution of known age group, race/ethnicity, and sex data, respectively. As a result of this procedure, incidence and rate data stratified by one or more of the variables - age group, race/ethnicity, and sex - may not accurately reflect total national incidence or rates.

Classification of STD Morbidity Reporting Sources

Prior to 1996, states classified the source of case reports as either private source (including private physicians, and private hospitals and institutions) or public (clinic) source (primarily STD clinics). As states began reporting morbidity data electronically in 1996, the classification categories for source of case reports expanded to include the following data sources: STD clinics, HIV counseling and testing sites, drug treatment clinics, family planning clinics, prenatal/obstetrics clinics, tuberculosis clinics, private physicians/HMOs, hospitals (inpatient),

emergency rooms, correctional facilities, laboratories, blood banks, National Job Training Program, school-based clinics, mental health providers, military, Indian Health Service, and other unspecified sources. Analysis of the data reported electronically after 1996 confirmed that the new STD clinic source of report data corresponded to the earlier reporting source category, public (clinic) source. Therefore, source of case report data for the period 1984–2006 are presented as STD clinic or non-STD clinic only (Table A2).

Definition of DHHS Regions

The ten U.S. Department of Health and Human Services (DHHS) regions referred to in the text and figures include the following jurisdictions: Region I = Connecticut, Maine, Massachusetts, New Hampshire, Rhode Island, and Vermont; Region II = New Jersey, New York, Puerto Rico, and U.S. Virgin Islands; Region III = Delaware, District of Columbia, Maryland, Pennsylvania, Virginia, and West Virginia; Region IV = Alabama, Florida, Georgia, Kentucky, Mississippi, North Carolina, South Carolina, and Tennessee; Region V = Illinois, Indiana, Michigan, Minnesota, Ohio, and Wisconsin; Region VI = Arkansas, Louisiana, New Mexico, Oklahoma, and Texas; Region VII = Iowa, Kansas, Missouri, and Nebraska; Region VIII = Colorado, Montana, North Dakota, South Dakota, Utah, and Wyoming; Region IX = Arizona, California, Guam, Hawaii, and Nevada; and Region X = Alaska, Idaho, Oregon, and Washington.

Chlamydia Morbidity Reporting

Trends in chlamydia morbidity reporting from many areas are more reflective of changes in diagnosis, screening, and reporting practices than of actual trends in disease incidence. As areas develop chlamydia prevention and control programs, including improved surveillance systems to monitor trends, the data should

improve and become more representative of true trends in disease.

Syphilis Morbidity Reporting

“Total syphilis” or “all stages of syphilis” includes primary, secondary, latent (including early latent, late latent, and latent syphilis of unknown duration), neurosyphilis, late (including late syphilis with clinical manifestations other than neurosyphilis), and congenital syphilis.

In 1996, the syphilis stage, “late syphilis with clinical manifestations other than neurosyphilis (late benign and cardiovascular syphilis)”, was added to the syphilis case definition (see STD Case Definitions in this **Appendix**).

While neurosyphilis can occur at almost any stage of syphilis, between 1996 and 2005, it was classified and reported as one of several mutually exclusive stages of syphilis. Beginning in 2005, neurosyphilis was no longer classified or reported as a distinct stage of syphilis. The Division of STD Prevention is reviewing these data collection and reporting changes to determine their impact on syphilis surveillance case definitions.

Congenital Syphilis Morbidity Reporting

In 1988, the surveillance case definition for congenital syphilis was changed. This case definition has greater sensitivity than the former definition.² In addition, many areas have greatly enhanced active case finding for congenital syphilis since 1988. For these reasons, the number of reported cases increased dramatically during 1989–1991. All reporting areas had implemented the new case definition for reporting congenital syphilis by January 1, 1992.

In addition to changing the case definition for congenital syphilis, CDC introduced a new data collection form (CDC 73.126) in 1990 (revised October 2003). Since 1995,

the data collected on this form have been used for reporting congenital syphilis cases and associated rates. This form is used to collect individual case information which allows more thorough analysis of case characteristics. For the purpose of analyses by race/ethnicity, if either the race or ethnicity question was answered, the case was included. For example, if “white” race was marked, but ethnicity was left blank, the individual was counted as “non-Hispanic white”. Congenital syphilis cases were reported by state and city of residence of the mother for the period 1995 through 2006.

Chlamydia, Gonorrhea, and Syphilis Prevalence Monitoring

Chlamydia and gonorrhea test positivity and syphilis seroreactivity were calculated for the following: women attending family planning clinics and prenatal clinics, men and women entering the National Job Training Program, men attending STD clinics and primary care clinics participating in the MSM Prevalence Monitoring Project, and men and women entering corrections facilities. Positivity was calculated by dividing the number of positive tests for chlamydia, gonorrhea, or syphilis (numerator) by the total number of positive and negative tests for each disease (denominator) and was expressed as a percentage. Except for the National Job Training Program screening data, these data sources may include more than one test from the same individual if that person was tested more than once during a year.

To increase the stability of the annual National Job Training Program prevalence estimates, chlamydia or gonorrhea prevalence data are presented when valid test results for 100 or more students per year are available for the population subgroup and state. The majority of the National Job Training Program’s chlamydia screening tests are tested by a single national contract laboratory which provides

those data to CDC. Gonorrhea screening tests for male and female students in many training centers are tested by local laboratories; these data are not available to CDC. To insure that state-specific gonorrhea screening data presented here are representative of all students entering training centers, gonorrhea test results for students at centers submitting specimens to the national contract laboratory are included only if the number of gonorrhea tests submitted is greater than 90% of the number of chlamydia tests submitted from the same center for the same time period.

Various laboratory test methods were used for all of these data sources except the National Job Training Program. For most of the figures presenting test positivity or prevalence data, no adjustments of test positivity based on laboratory test type and sensitivity were made. However, for Figure 10 and Figure J, the chlamydia test results for each test type were weighted to reflect the sensitivity of the test used.³ The weights used in this adjustment are the reciprocals of the sensitivities of the laboratory test methods used. These test type-specific sensitivities were estimates derived from published evaluations of chlamydia screening tests.^{4,5} Limitations of this adjustment include: unknown dates when laboratories changed tests, missing information on the test method, variation of test sensitivity within a technology type, and no adjustment for supplemental testing such as negative grey zone testing. For more details on chlamydia prevalence, refer to the following annual publication: Centers for Disease Control and Prevention. *Sexually Transmitted Disease Surveillance 2006 Supplement: Chlamydia Prevalence Monitoring Project Annual Report 2006*. Atlanta, GA: U.S. Department of Health and Human Services (available first quarter 2008).

In the MSM Prevalence Monitoring Project the syphilis seroreactivity data in most instances do not reflect confirmatory testing

and thus biologic false positive test results were not systematically excluded. The extent to which these data reflect prevalence of active syphilis infection varies by site. Similarly, in the Corrections Prevalence Monitoring Project, syphilis seroreactivity test results were not confirmed. Only a few juvenile corrections sites submitted data to CDC, making overall interpretation difficult due to the small sample size. Because only selected corrections facilities participated in the Corrections Prevalence Monitoring Project, state-specific positivity for syphilis, chlamydia, and gonorrhea may not be representative of all corrections facilities in the state.

Prevalence data for region- and state-specific figures were published with permission from the Regional Infertility Prevention Program, selected state STD prevention programs, and the National Job Training Program.

Gonococcal Isolate Surveillance Project (GISP)

Data on antimicrobial susceptibility in *Neisseria gonorrhoeae* were collected through the Gonococcal Isolate Surveillance Project (GISP), a sentinel system of 28 STD clinics and five regional laboratories located throughout the United States. For more details on findings from GISP gonorrhea surveillance activities, refer to the following annual publication: Centers for Disease Control and Prevention. *Sexually Transmitted Disease Surveillance 2006 Supplement: Gonococcal Isolate Surveillance Project (GISP) Annual Report 2006*. Atlanta, GA: U.S. Department of Health and Human Services (available first quarter 2008).

Other Surveillance Data Sources

National Disease and Therapeutic Index (NDTI)

The information on the number of initial visits to private physicians' offices for sexually transmitted diseases was based on analysis of data from the National Disease and Therapeutic Index (NDTI) (machine-readable files or summary statistics for the period 1966 through 2006). The NDTI is a probability sample survey of private physicians' clinical management practices. For more information on this database, contact IMS Health, 660 W. Germantown Pike, Plymouth Meeting, PA 19462; Telephone: (800) 523-5333.

National Hospital Discharge Survey (NHDS)

The information on patients hospitalized for pelvic inflammatory disease or ectopic pregnancy was based on analysis of data from the National Hospital Discharge Survey (machine-readable files for years 1980–2005), an ongoing nation wide sample survey of medical records of patients discharged from acute care hospitals in the United States, conducted by the National Center for Health Statistics. For more information, see *Graves EJ; 1988 Summary: National Hospital Discharge Survey; Advance data No. 185; Hyattsville (MD): National Center for Health Statistics, 1990*.

National Hospital Ambulatory Medical Care Survey (NHAMCS-ER)

The National Hospital Ambulatory Medical Care Survey (NHAMCS-ER) (machine-readable files for 1995–2005) was used to obtain estimates of the number of emergency room visits for pelvic inflammatory disease among women ages 15 to 44 years. The estimates generated using these data sources (NHDS and

NHAMCS-ER) are based on statistical surveys and therefore have sampling variability associated with the estimates.

Healthy People 2010 Objectives

*Healthy People 2010*⁶ is a set of health objectives for the U.S. to achieve over the first decade of the new century. It is used by people, States, communities, professional organizations, and others to help develop programs to improve health. *HP2010* builds on initiatives pursued over the past two decades. The 1979 Surgeon General's Report, *Healthy People, and Healthy People 2000: National Health Promotion and Disease Prevention Objectives* established national health objectives and served as the basis for the development of State and community plans. Like its predecessors, *Healthy People 2010* was developed through a broad consultation process, built on the best scientific knowledge and designed to measure programs over time. *Healthy People 2010* is organized into 28 focus areas, each with objectives and measures designed to drive action that will support two overarching goals: 1) increasing the quality and years of healthy life and 2) eliminating health disparities.

Focus area 25 of *Healthy People 2010* –Sexually Transmitted Diseases, – contains objectives and measures related to STDs. The baselines, *HP2010* targets and annual progress toward the targets are reported in Table A3. The year 2010 targets for the diseases addressed in this report are: primary and secondary syphilis–0.2 case

per 100,000 population; congenital syphilis–1.0 case per 100,000 live births; and gonorrhea–19.0 cases per 100,000 population. An additional target established in the *HP2010* objectives is to reduce the *Chlamydia trachomatis* test positivity to 3% among females aged 15 to 24 years who attend family planning and STD clinics and among males aged 15 to 24 who attend STD clinics.

Government Performance and Results Act of 1993 (GPRA) Goals

The Government Performance and Results Act of 1993 (GPRA) was enacted by Congress to increase the confidence of citizens in the capability of the federal government, to increase the effectiveness and accountability of federal programs, to improve service delivery, to provide agencies a uniform tool for internal management and to assist Congressional decision making. GPRA requires each agency to have a performance plan with long-term outcomes and annual, measurable performance goals and to report on these plans annually, comparing results with annual goals. There are two STD GPRA goals: 1) reduction in pelvic inflammatory disease (PID) and 2) elimination of syphilis. Each of these goals has measures. The long-term goals and measures of progress are reported in Table A4.

¹ Office of Management and Budget. Standards for Defining Metropolitan and Micropolitan Statistical Areas: Notice Federal Register December 27, 2000; 65(249): 82228-38

² Kaufman RE, Jones OG, Blount JH, Wiesner PJ. Questionnaire survey of reported early congenital syphilis: problems in diagnosis, prevention, and treatment. *Sexually Transmitted Diseases* 1977;4:135-9.

³ Webster Dicker L, Mosure DJ, Levine WC, Black CM, Berman SM. The impact of switching laboratory tests on reported trends in *Chlamydia trachomatis* infections. *Am J Epidemiol* 2000;151:430-435.

⁴ Newhall WJ, DeLisle S, Fine D, et al. Head-to-head evaluation of five different non-culture chlamydia tests relative to a quality-assured culture standard. *Sexually Transmitted Diseases* 1994;21:S165-6.

⁵ Black CM, Marrazzo J, Johnson RE, et al. Head-to-head multi center comparison of DNA probe and nucleic acid amplification tests for *Chlamydia trachomatis* infection in women performed with an improved reference standard. *J Clin Micro* 2002;40:3757-3763.

⁶ U.S. Department of Health and Human Services. *Healthy People 2010* 2nd ed. With Understanding and Improving Health and Objectives for Improving Health. 2 vols. Washington, DC: U.S. Government Printing Office, November 2000.

Table A1. Selected STDs — Percentage of unknown, missing, or invalid values for selected variables by state and by nationally notifiable STD, 2006

State	Primary and Secondary Syphilis				Gonorrhea			Chlamydia		
	Percent Unknown Race/Ethnicity	Percent Unknown Age	Percent Unknown Sex	Percent Unknown Sex of Partners	Percent Unknown Race/Ethnicity	Percent Unknown Age	Percent Unknown Sex	Percent Unknown Race/Ethnicity	Percent Unknown Age	Percent Unknown Sex
Alabama	3.1	0.0	0.0	23.8	28.9	1.0	0.0	31.3	0.6	0.1
Alaska	0.0	0.0	0.0	100.0	0.2	0.0	0.0	0.0	0.0	0.0
Arizona	14.8	0.0	2.0	35.5	24.5	0.0	0.1	30.3	0.0	0.1
Arkansas	0.0	0.0	0.0	36.4	3.4	0.3	0.0	4.2	0.5	0.0
California	3.4	0.3	0.1	11.4	33.4	0.7	0.6	34.1	0.5	0.5
Colorado	5.8	0.0	0.0	8.7	27.1	0.0	0.0	42.0	0.4	0.0
Connecticut	1.6	0.0	0.0	0.0	25.9	0.3	0.0	34.1	1.1	0.0
Delaware	0.0	0.0	0.0	100.0	1.0	0.0	0.0	1.9	0.0	0.0
District of Columbia	0.9	0.0	0.0	18.1	22.3	0.8	0.4	46.5	0.6	1.2
Florida	4.2	0.0	0.0	39.6	9.8	0.2	0.0	14.2	0.3	0.0
Georgia	2.9	0.2	0.0	21.3	38.6	1.3	0.8	50.2	1.4	0.9
Hawaii	0.0	0.0	0.0	22.2	41.2	0.3	0.0	49.6	0.3	0.1
Idaho*	33.3	0.0	0.0	33.3	24.8	0.0	0.5	21.5	0.1	0.4
Illinois	3.7	0.0	0.0	9.7	12.8	0.0	0.0	15.8	0.0	0.0
Indiana	2.2	0.0	0.0	7.5	13.4	0.4	0.4	16.9	0.7	0.5
Iowa	0.0	0.0	0.0	42.1	9.3	0.1	0.0	11.9	0.2	0.0
Kansas	0.0	0.0	0.0	18.5	22.7	0.2	0.0	28.9	0.2	0.0
Kentucky	4.1	1.4	0.0	21.9	22.0	0.5	0.2	26.5	0.3	0.3
Louisiana	0.9	0.0	0.0	100.0	16.0	0.4	0.8	25.0	0.6	1.2
Maine*	0.0	0.0	0.0	0.0	10.9	0.0	0.0	20.0	0.4	0.0
Maryland	0.7	0.0	0.0	9.7	25.9	0.4	0.2	36.5	0.5	0.4
Massachusetts	4.8	0.0	0.0	8.9	31.4	0.3	0.1	39.5	0.5	0.2
Michigan	0.8	0.0	0.0	100.0	46.8	0.2	0.2	47.3	0.2	0.3
Minnesota	6.4	0.0	0.0	0.0	14.4	0.0	0.0	15.4	0.0	0.0
Mississippi	3.5	0.0	0.0	5.8	15.2	0.1	0.0	17.8	0.1	0.0
Missouri	0.0	0.0	0.0	4.8	17.1	0.1	0.0	22.9	0.1	0.0
Montana*	0.0	0.0	0.0	0.0	24.7	0.0	0.0	17.2	0.6	0.3
Nebraska*	0.0	0.0	0.0	28.6	25.9	0.2	1.1	24.2	0.4	1.3
Nevada	17.5	0.0	0.0	2.9	31.1	0.5	0.0	38.8	0.3	0.0
New Hampshire	0.0	0.0	0.0	0.0	12.2	0.0	0.0	8.9	0.0	0.0
New Jersey	2.9	0.0	0.0	12.1	37.9	0.7	0.1	46.2	1.0	0.1
New Mexico	3.8	0.0	0.0	10.1	8.5	0.2	0.0	7.6	0.3	0.1
New York	19.8	0.0	0.0	38.5	38.2	0.4	0.0	42.7	0.5	0.0
North Carolina	0.3	0.0	0.0	100.0	1.2	0.0	0.0	1.5	0.0	0.0
North Dakota*	0.0	0.0	0.0	100.0	3.9	0.0	0.0	9.3	0.0	0.1
Ohio	2.2	0.0	0.0	7.6	29.0	2.0	1.0	34.7	2.7	1.5
Oklahoma	1.4	0.0	0.0	5.7	2.4	0.0	0.0	2.6	0.0	0.0
Oregon	3.4	0.0	0.0	100.0	6.3	0.0	0.0	11.0	0.0	0.0
Pennsylvania	1.9	0.0	0.0	2.3	22.6	0.4	0.0	24.5	0.1	0.0
Rhode Island	0.0	0.0	0.0	7.1	10.4	0.0	0.0	24.9	0.1	0.2
South Carolina	0.0	0.0	0.0	16.7	29.1	0.9	0.1	37.6	0.6	0.1
South Dakota	0.0	0.0	0.0	7.7	0.0	0.8	0.0	0.3	1.6	0.0
Tennessee	0.0	0.0	0.0	2.4	13.5	0.1	0.0	17.7	0.1	0.0
Texas	0.2	0.0	0.0	2.4	9.2	0.3	0.1	8.6	0.2	0.1
Utah	0.0	0.0	0.0	14.3	3.9	0.0	0.0	4.9	0.1	0.0
Vermont*	33.3	0.0	0.0	33.3	0.0	0.0	0.0	0.3	0.0	0.0
Virginia	0.0	0.0	0.0	3.2	3.0	0.1	0.0	10.3	0.1	0.1
Washington	4.9	0.0	0.0	14.8	20.4	0.9	0.0	20.1	1.0	0.0
West Virginia	18.2	0.0	0.0	9.1	11.0	0.1	0.0	11.5	0.3	0.1
Wisconsin	0.0	0.0	0.0	4.4	23.5	0.0	0.1	27.1	0.0	0.2
Wyoming*	0.0	0.0	0.0	0.0	13.3	4.2	0.0	25.2	1.3	0.0
U.S. TOTAL	4.1	0.1	0.1	22.7	21.6	0.5	0.2	26.3	0.5	0.2

*Percentages for P&S syphilis are based on less than 10 cases.

NOTE: "Unknown" includes unknown, missing, or invalid data values.

Table A2. Reported cases of sexually transmitted disease reporting source and by sex: United States, 2006

<i>Disease</i>	<i>Non-STD Clinic</i>			<i>STD Clinic</i>			<i>Total*</i>		
	<i>Male</i>	<i>Female</i>	<i>Total</i>	<i>Male</i>	<i>Female</i>	<i>Total</i>	<i>Male</i>	<i>Female</i>	<i>Total</i>
Chlamydia	156,390	629,883	787,878	82,638	93,169	175,977	252,630	775,788	1,030,911
Gonorrhea	93,744	139,217	233,429	64,582	31,238	95,923	170,508	187,033	358,366
Primary Syphilis	1,418	141	1,559	917	132	1,049	2,400	278	2,678
Secondary Syphilis	4,029	749	4,781	1,713	399	2,114	5,893	1,180	7,078
Early Latent Syphilis	4,280	1,623	5,906	2,129	915	3,047	6,581	2,599	9,186
Late and Late Latent Syphilis [†]	8,030	4,929	12,972	2,682	1,637	4,319	10,915	6,716	17,644
Chancroid	7	7	14	5	12	17	12	21	33

*Totals include unknown sex and reporting source.

[†]Late and late latent syphilis includes late latent syphilis, latent syphilis of unknown duration, neurosyphilis, and late syphilis with clinical manifestations other than neurosyphilis.

See Appendix (Classification of STD Morbidity Reporting Source).

Table A3. Healthy People 2010 Sexually Transmitted Diseases Objective Status

<i>HP 2010 Objectives</i>		<i>Baseline Year</i>	<i>Baseline</i>	<i>2002</i>	<i>2003</i>	<i>2004</i>	<i>2005</i>	<i>2006</i>	<i>HP 2010 Target</i>
25-1	Reduce the proportion of adolescents and young adults with <i>Chlamydia trachomatis</i> infections								
	a. Females aged 15 to 24 years attending family planning clinics	1997	5.0%	6.0%*	6.4%*	6.9%*	6.9%*	7.1%*	3.0%
	b. Females aged 15 to 24 years attending STD clinics	1997	12.2%	13.5%*	14.1%*	15.3%*	15.4%*	14.8%*	3.0%
	c. Males aged 15 to 24 years attending STD clinics	1997	15.7%	17.5%*	19.3%*	20.8%*	20.5%*	20.8%*	3.0%
25-2	Reduce gonorrhea (cases per 100,000 population)	1997	123.0	122.0	115.2	112.4	114.6	120.9	19.0
25-3	Eliminate sustained domestic transmission of primary and secondary syphilis (cases per 100,000 population)	1997	3.2	2.4	2.5	2.7	2.9	3.3	0.2
25-4	Reduce the proportion of adults aged 20 to 29 years with genital herpes infection	1988-94	17.0%	11.0%	NA	NA	NA	NA	14.0%
25-6	Reduce the proportion of females aged 15 to 44 years who have ever required treatment for pelvic inflammatory disease (PID)	1995	8.0%	5.0%	NA	NA	NA	NA	5.0%
25-7	Reduce the proportion of childless females with fertility problems who have had a sexually transmitted disease or who have required treatment for pelvic inflammatory disease (PID)	1995	27.0%	22.0%	NA	NA	NA	NA	15.0%
25-9	Reduce congenital syphilis (cases per 100,000 live births)	1997	27.0	11.4	10.6	9.1	8.2	8.5	1.0

<i>HP 2010 Objective</i>	<i>Data Source</i>
25-1	STD Surveillance System (STDSS), CDC, NCHHSTP.
25-2	STD Surveillance System (STDSS), CDC, NCHHSTP.
25-3	STD Surveillance System (STDSS), CDC, NCHHSTP.
25-4	National Health and Nutrition Examination Survey (NHANES), CDC, NCHS.
25-6	National Survey of Family Growth (NSFG), CDC, NCHS.
25-7	National Survey of Family Growth (NSFG), CDC, NCHS.
25-9	STD Surveillance System (STDSS), CDC, NCHHSTP.

*Overall positivity not adjusted for changes in laboratory test method and associated increases in test sensitivity.

NOTE: Healthy People 2010 developmental objectives are not addressed in this report.

NA=Not available.

Table A4. Government Performance Results Act (GPRA) Sexually Transmitted Diseases Goals and Measures

<i>GPRA Goals</i>	<i>Baseline</i>	<i>Actual Performance</i>		<i>Long-Term Goal</i>
	<i>2002</i>	<i>2005</i>	<i>2006</i>	<i>2010</i>
Goal 1: Reduction in PID (as measured by initial visits to physicians in women 15-44 years of age)	197,000	176,000	106,000	168,000
a. Prevalence of Chlamydia in high-risk women ≤ 25 years	10.1%*	9.2%*	13.1%*	8.6%*
b. Prevalence of Chlamydia in women ≤ 25 years in family planning clinics	5.6%*	6.3%*	6.7%*	4.9%*
c. Incidence of Gonorrhea/100,000 population in women 15-44 years of age	279	275	290	237
Goal 2: Elimination of Syphilis (as measured by incidence of P&S Syphilis/100,000 population)	2.4	2.9	3.3	2.2
a. Incidence of P&S Syphilis/100,000 population - men	3.8	5.1	5.7	4.2
b. Incidence of P&S Syphilis/100,000 population - women	1.1	0.9	1.0	0.38
c. Incidence of Congenital Syphilis/100,000 live births	10.2	8.2	8.5	3.9
d. Black:white rate ratio of P&S Syphilis	8:1	5.4:1	5.9:1	3:1

<i>GPRA Goals</i>	<i>Data Source</i>
1	National Disease and Therapeutic Index (IMS Health).
1-a	National Job Training Program.
1-b	Regional Infertility Prevention Projects (IPP)
1-c	STD Surveillance System (STDSS), CDC, NCHHSTP.
2	STD Surveillance System (STDSS), CDC, NCHHSTP.
2-a	STD Surveillance System (STDSS), CDC, NCHHSTP.
2-b	STD Surveillance System (STDSS), CDC, NCHHSTP.
2-c	STD Surveillance System (STDSS), CDC, NCHHSTP.
2-d	STD Surveillance System (STDSS), CDC, NCHHSTP.

*Median state-specific chlamydia prevalence among women was not adjusted for changes in laboratory test method and associated increases in test sensitivity.

STD Surveillance Case Definitions

PART 1. CASE DEFINITIONS¹ FOR NATIONALLY NOTIFIABLE INFECTIOUS DISEASES

Chancroid (Revised 9/96)

Clinical description

A sexually transmitted disease characterized by painful genital ulceration and inflammatory inguinal adenopathy. The disease is caused by infection with *Haemophilus ducreyi*.

Laboratory criteria for diagnosis

- Isolation of *H. ducreyi* from a clinical specimen

Case classification

Probable: a clinically compatible case with both a) no evidence of *Treponema pallidum* infection by darkfield microscopic examination of ulcer exudate or by a serologic test for syphilis performed ≥ 7 days after onset of ulcers and b) either a clinical presentation of the ulcer(s) not typical of disease caused by herpes simplex virus (HSV) or a culture negative for HSV.

Confirmed: a clinically compatible case that is laboratory confirmed

Chlamydia trachomatis, Genital Infections (Revised 9/96)

Clinical description

Infection with *Chlamydia trachomatis* may result in urethritis, epididymitis, cervicitis, acute salpingitis, or other syndromes when sexually transmitted; however, the infection is often asymptomatic in women. Perinatal infections may result in inclusion conjunctivitis and pneumonia in newborns. Other syndromes caused by *C. trachomatis* include lymphogranuloma venereum (see Lymphogranuloma Venereum) and trachoma.

Laboratory criteria for diagnosis

- Isolation of *C. trachomatis* by culture or
- Demonstration of *C. trachomatis* in a clinical specimen by detection of antigen or nucleic acid

Case classification

Confirmed: a case that is laboratory confirmed

Gonorrhea (Revised 9/96)

Clinical description

A sexually transmitted infection commonly manifested by urethritis, cervicitis, or salpingitis. Infection may be asymptomatic.

Laboratory criteria for diagnosis

- Isolation of typical gram-negative, oxidase-positive diplococci (presumptive *Neisseria gonorrhoeae*) from a clinical specimen, or

- Demonstration of *N. gonorrhoeae* in a clinical specimen by detection of antigen or nucleic acid, or
- Observation of gram-negative intracellular diplococci in a urethral smear obtained from a male

Case classification

Probable: a) demonstration of gram-negative intracellular diplococci in an endocervical smear obtained from a female or b) a written morbidity report of gonorrhea submitted by a physician

Confirmed: a case that is laboratory confirmed

Syphilis (All Definitions Revised 9/96)

Syphilis is a complex sexually transmitted disease that has a highly variable clinical course. Classification by a clinician with expertise in syphilis may take precedence over the following case definitions developed for surveillance purposes.

Syphilis, primary

Clinical description

A stage of infection with *Treponema pallidum* characterized by one or more chancres (ulcers); chancres might differ considerably in clinical appearance.

Laboratory criteria for diagnosis

- Demonstration of *T. pallidum* in clinical specimens by darkfield microscopy, direct fluorescent antibody (DFA-TP), or equivalent methods

Case classification

Probable: a clinically compatible case with one or more ulcers (chancres) consistent with primary syphilis and a reactive serologic test (nontreponemal: Venereal Disease Research Laboratory [VDRL] or rapid plasma reagin [RPR]; treponemal: fluorescent treponemal antibody absorbed [FTA-ABS] or microhemagglutination assay for antibody to *T. pallidum* [MHA-TP])

Confirmed: a clinically compatible case that is laboratory confirmed

Syphilis, secondary

Clinical description

A stage of infection caused by *T. pallidum* and characterized by localized or diffuse mucocutaneous lesions, often with generalized lymphadenopathy. The primary chancre may still be present.

Laboratory criteria for diagnosis

- Demonstration of *T. pallidum* in clinical specimens by darkfield microscopy, DFATP, or equivalent methods

Case classification

Probable: a clinically compatible case with a nontreponemal (VDRL or RPR) titer ≥ 4

Confirmed: a clinically compatible case that is laboratory confirmed

Syphilis, latent

Clinical description

A stage of infection caused by *T. pallidum* in which organisms persist in the body of the infected person without causing symptoms or signs. Latent syphilis is subdivided into early, late, and unknown categories based on the duration of infection.

Case classification

Probable: no clinical signs or symptoms of syphilis and the presence of one of the following:

- No past diagnosis of syphilis, a reactive nontreponemal test (i.e., VDRL or RPR), and a reactive treponemal test (i.e., FTA-ABS or MHA-TP)
- A past history of syphilis therapy and a current nontreponemal test titer demonstrating fourfold or greater increase from the last nontreponemal test titer

Syphilis, early latent

Clinical description

A subcategory of latent syphilis. When initial infection has occurred within the previous 12 months, latent syphilis is classified as early latent.

Case classification

Probable: latent syphilis (see Syphilis, latent) in a person who has evidence of having acquired the infection within the previous 12 months based on one or more of the following criteria:

- Documented seroconversion or fourfold or greater increase in titer of a nontreponemal test during the previous 12 months
- A history of symptoms consistent with primary or secondary syphilis during the previous 12 months
- A history of sexual exposure to a partner who had confirmed or probable primary or secondary syphilis or probable early latent syphilis (documented independently as duration < 1 year)
- Reactive nontreponemal and treponemal tests from a person whose only possible exposure occurred within the preceding 12 months

Syphilis, late latent

Clinical description

A subcategory of latent syphilis. When initial infection has occurred > 1 year previously, latent syphilis is classified as late latent.

Case classification

Probable: latent syphilis (see Syphilis, latent) in a patient who has no evidence of having acquired the disease within the preceding 12 months (see Syphilis, early latent) and whose age and titer do not meet the criteria specified for latent syphilis of unknown duration.

Syphilis, latent, of unknown duration

Clinical description

A subcategory of latent syphilis. When the date of initial infection cannot be established as having occurred within the previous year and the patient's age and titer meet criteria described below, latent syphilis is classified as latent syphilis of unknown duration.

Case classification

Probable: latent syphilis (see Syphilis, latent) that does not meet the criteria for early latent syphilis, and the patient is aged 13–35 years and has a nontreponemal titer ≥ 32

Neurosyphilis

Clinical description

Evidence of central nervous system infection with *T. pallidum*

Laboratory criteria for diagnosis

- A reactive serologic test for syphilis and reactive VDRL in cerebrospinal fluid (CSF)

Case classification

Probable: syphilis of any stage, a negative VDRL in CSF, and both the following:

- Elevated CSF protein or leukocyte count in the absence of other known causes of these abnormalities
- Clinical symptoms or signs consistent with neurosyphilis without other known causes for these clinical abnormalities

Confirmed: syphilis of any stage that meets the laboratory criteria for neurosyphilis

Syphilis, late, with clinical manifestations other than neurosyphilis (late benign syphilis and cardiovascular syphilis)

Clinical description

Clinical manifestations of late syphilis other than neurosyphilis may include inflammatory lesions of the cardiovascular system, skin, and bone. Rarely, other structures (e.g., the upper and lower respiratory tracts, mouth, eye, abdominal organs, reproductive organs, lymph nodes, and skeletal muscle) may be involved. Late syphilis usually becomes clinically manifest only after a period of 15–30 years of untreated infection.

Laboratory criteria for diagnosis

Demonstration of *T. pallidum* in late lesions by fluorescent antibody or special stains (although organisms are rarely visualized in late lesions)

Case classification

Probable: characteristic abnormalities or lesions of the cardiovascular system, skin, bone, or other structures with a reactive treponemal test, in the absence of other known causes of these abnormalities, and without CSF abnormalities and clinical symptoms or signs consistent with neurosyphilis

Confirmed: a clinically compatible case that is laboratory confirmed

Comment

Analysis of CSF for evidence of neurosyphilis is necessary in the evaluation of late syphilis with clinical manifestations.

Syphilitic Stillbirth

Clinical description

A fetal death that occurs after a 20-week gestation or in which the fetus weighs > 500 g and the mother had untreated or inadequately treated* syphilis at delivery

Comment

For reporting purposes, syphilitic stillbirths should be reported as cases of congenital syphilis.

Syphilis, Congenital (Revised 9/96)

Clinical description

A condition caused by infection in utero with *Treponema pallidum*. A wide spectrum of severity exists, and only severe cases are clinically apparent at birth. An infant or child (aged < 2 years) may have signs such as hepatosplenomegaly, rash, condyloma lata, snuffles, jaundice (nonviral hepatitis), pseudoparalysis, anemia, or edema (nephrotic syndrome and/or malnutrition). An older child may have stigmata (e.g., interstitial keratitis, nerve deafness, anterior bowing of shins, frontal bossing, mulberry molars, Hutchinson teeth, saddle nose, rhagades, or Clutton joints).

Laboratory criteria for diagnosis

Demonstration of *T. pallidum* by darkfield microscopy, fluorescent antibody, or other specific stains in specimens from lesions, placenta, umbilical cord, or autopsy material

Case classification

Probable: a condition affecting an infant whose mother had untreated or inadequately treated* syphilis at delivery, regardless of signs in the infant, or an infant or child who has a reactive treponemal test for syphilis and any one of the following:

- Any evidence of congenital syphilis on physical examination
- Any evidence of congenital syphilis on radiographs of long bones
- A reactive cerebrospinal fluid (CSF) venereal disease research laboratory (VDRL)
- An elevated CSF cell count or protein (without other cause)
- A reactive fluorescent treponemal antibody absorbed—19S-IgM antibody test or IgM enzyme-linked immunosorbent assay

Confirmed: a case that is laboratory confirmed

Comment

Congenital and acquired syphilis may be difficult to distinguish when a child is seropositive after infancy. Signs of congenital syphilis may not be obvious, and stigmata may not yet have developed. Abnormal values for CSF VDRL, cell count, and protein, as well as IgM antibodies, may be found in either congenital or acquired syphilis. Findings on radiographs of long bones may help because radiographic changes in the metaphysis and epiphysis are considered classic signs of congenitally acquired syphilis. The decision may ultimately be based on maternal history and clinical judgment. In a young child, the possibility of sexual abuse should be considered as a cause of acquired rather than congenital syphilis, depending on the clinical picture. For reporting purposes, congenital syphilis includes cases of congenitally acquired syphilis among infants and children as well as syphilitic stillbirths.

*Inadequate treatment consists of any nonpenicillin therapy or penicillin administered < 30 days before delivery.

PART 2. CASE DEFINITIONS¹ FOR NON-NOTIFIABLE INFECTIOUS DISEASES

Genital Herpes (Herpes Simplex Virus) (Revised 9/96)

Clinical description

A condition characterized by visible, painful genital or anal lesions

Laboratory criteria for diagnosis

- Isolation of herpes simplex virus from cervix, urethra, or anogenital lesion, or
- Demonstration of virus by antigen detection technique in clinical specimens from cervix, urethra, or anogenital lesion, or
- Demonstration of multinucleated giant cells on a Tzanck smear of scrapings from an anogenital lesion

Case classification

Probable: a clinically compatible case (in which primary and secondary syphilis have been excluded by appropriate serologic tests and darkfield microscopy, when available) with either a diagnosis of genital herpes based on clinical presentation (without laboratory confirmation) or a history of one or more previous episodes of similar genital lesions

Confirmed: a clinically compatible case that is laboratory confirmed

Comment

Genital herpes should be reported only once per patient. The first diagnosis for a patient with no previous diagnosis should be reported.

Genital Warts (Revised 9/96)

Clinical description

An infection characterized by the presence of visible, exophytic (raised) growths on the internal or external genitalia, perineum, or perianal region

Laboratory criteria for diagnosis

- Histopathologic changes characteristic of human papillomavirus infection in specimens obtained by biopsy or exfoliative cytology or
- Demonstration of virus by antigen or nucleic acid detection in a lesion biopsy

Case classification

Probable: a clinically compatible case without histopathologic diagnosis and without microscopic or serologic evidence that the growth is the result of secondary syphilis

Confirmed: a clinically compatible case that is laboratory confirmed

Comment

Genital warts should be reported only once per patient. The first diagnosis for a patient with no previous diagnosis should be reported.

Granuloma Inguinale

Clinical description

A slowly progressive ulcerative disease of the skin and lymphatics of the genital and perianal area caused by infection with *Calymmatobacterium granulomatis*. A clinically compatible case would have one or more painless or minimally painful granulomatous lesions in the anogenital area.

Laboratory criteria for diagnosis

- Demonstration of intracytoplasmic Donovan bodies in Wright or Giemsa-stained smears or biopsies of granulation tissue

Case classification

Confirmed: a clinically compatible case that is laboratory confirmed

Lymphogranuloma Venereum**Clinical description**

Infection with L1, L2, or, L3 serovars of *Chlamydia trachomatis* may result in a disease characterized by genital lesions, suppurative regional lymphadenopathy, or hemorrhagic proctitis. The infection is usually sexually transmitted.

Laboratory criteria for diagnosis

- Isolation of *C. trachomatis*, serotype L1, L2, or L3 from clinical specimen, or
- Demonstration by immunofluorescence of inclusion bodies in leukocytes of an inguinal lymph node (bubo) aspirate, or
- Positive microimmunofluorescent serologic test for a lymphogranuloma venereum strain of *C. trachomatis*

Case classification

Probable: a clinically compatible case with one or more tender fluctuant inguinal lymph nodes or characteristic proctogenital lesions with supportive laboratory findings of a single *C. trachomatis* complement fixation titer of > 64

Confirmed: a clinically compatible case that is laboratory confirmed

Mucopurulent Cervicitis (Revised 9/96)**Clinical description**

Cervical inflammation that is not the result of infection with *Neisseria gonorrhoeae* or *Trichomonas vaginalis*. Cervical inflammation is defined by the presence of one of the following criteria:

- Mucopurulent secretion (from the endocervix) that is yellow or green when viewed on a white, cotton-tipped swab (positive swab test)
- Induced endocervical bleeding (bleeding when the first swab is placed in the endocervix)

Laboratory criteria for diagnosis

- No evidence of *N. gonorrhoeae* by culture, Gram stain, or antigen or nucleic acid detection, and no evidence of *T. vaginalis* on wet mount

Case classification

Confirmed: a clinically compatible case in a female who does not have either gonorrhea or trichomoniasis

Comment

Mucopurulent cervicitis (MPC) is a clinical diagnosis of exclusion. The syndrome may result from infection with any of several agents (see *Chlamydia trachomatis*, Genital Infections). If gonorrhea, trichomoniasis, and chlamydia are excluded, a clinically compatible illness should be classified as

MPC. An illness in a female that meets the case definition of MPC and *C. trachomatis* infection should be classified as chlamydia.

Nongonococcal Urethritis (Revised 9/96)

Clinical description

Urethral inflammation that is not the result of infection with *Neisseria gonorrhoeae*. Urethral inflammation may be diagnosed by the presence of one of the following criteria:

- A visible abnormal urethral discharge, or
- A positive leukocyte esterase test from a male aged < 60 years who does not have a history of kidney disease or bladder infection, prostate enlargement, urogenital anatomic anomaly, or recent urinary tract instrumentation, or
- Microscopic evidence of urethritis (≥ 5 white blood cells per high-power field) on a Gram stain of a urethral smear

Laboratory criteria for diagnosis

- No evidence of *N. gonorrhoeae* infection by culture, Gram stain, or antigen or nucleic acid detection

Case classification

Confirmed: a clinically compatible case in a male in whom gonorrhea is not found, either by culture, Gram stain, or antigen or nucleic acid detection

Comment

Nongonococcal urethritis (NGU) is a clinical diagnosis of exclusion. The syndrome may result from infection with any of several agents (see *Chlamydia trachomatis*, Genital Infection). If gonorrhea and chlamydia are excluded, a clinically compatible illness should be classified as NGU. An illness in a male that meets the case definition of NGU and *C. trachomatis* infection should be classified as chlamydia.

Pelvic Inflammatory Disease (Revised 9/96)

Clinical case definition

A clinical syndrome resulting from the ascending spread of microorganisms from the vagina and endocervix to the endometrium, fallopian tubes, and/or contiguous structures. In a female who has lower abdominal pain and who has not been diagnosed as having an established cause other than pelvic inflammatory disease (PID) (e.g., ectopic pregnancy, acute appendicitis, and functional pain), all the following clinical criteria must be present:

- Lower abdominal tenderness, and
- Tenderness with motion of the cervix, and
- Adnexal tenderness

In addition to the preceding criteria, at least one of the following findings must also be present:

- Meets the surveillance case definition of *C. trachomatis* infection or gonorrhea
- Temperature > 100.4 F (> 38.0 C)
- Leukocytosis > 10,000 white blood cells/mm³
- Purulent material in the peritoneal cavity obtained by culdocentesis or laparoscopy

- Pelvic abscess or inflammatory complex detected by bimanual examination or by sonography
- Patient is a sexual contact of a person known to have gonorrhea, chlamydia, or nongonococcal urethritis

Case classification

Confirmed: a case that meets the clinical case definition

Comment

For reporting purposes, a clinician's report of PID should be counted as a case.

¹ Centers for Disease Control and Prevention. Case definitions for infectious conditions under public health surveillance, 1997. *MMWR* 1997;46(No. RR-10;1).

STD Project Directors, STD Program Managers, and State and Territorial Epidemiologists

We gratefully acknowledge the contributions of state STD project directors, STD program managers, and state and territorial epidemiologists to this report. The persons listed were in the positions shown as of September 14, 2007.

	STD Project Directors	STD Program Managers	State Epidemiologists
Alabama	Charles H. Woernle	Sandra Langston	John Lofgren
Alaska	Wendy Crator	Donna Cecere	Joe McLaughlin
Arizona	Judy Norton	Alfonso Urquidi	Kenneth Komatsu
Arkansas	Gary Horton	Mark Barnes	Jim Phillips
California	Gail Bolan	Romni Neiman	Gilberto Chavez
Los Angeles	Peter Kerndt	Mary Hayes	Gilberto Chavez
San Francisco	Jeffrey Klausner	Wendy Wolf	Gilberto Chavez
Colorado	Maureen Bush	Bob Bongiovanni	Ken Gershman
Connecticut	James L. Hadler	Heidi Jenkins	James L. Hadler
Delaware	James C. Welch	Catherine Mosley	Paula Eggers
District of Columbia	Karyn Berry	John Heath	John Davies-Cole
Florida	Russell Eggert	Karla Schmitt	John Middaugh
Georgia	Linda Smart-Smith	Russ Cantrell	Susan Lance
Hawaii	Peter Whiticar	Roy Ohye	Paul Effler
Idaho	Richard Armstrong	Vacant	Christine G. Hahn
Illinois	Charlie Rabins	Ed Renier	Craig Conover (Acting)
Chicago	Will Wong	John Paffel	Craig Conover (Acting)
Indiana	Jerry Burkman	Jim Beall	Robert Teclaw
Iowa	Julie McMahon	Karen Thompson	Patricia Quinlisk
Kansas	Brenda Walker	R. Allen Mayer	Gail Hansen
Kentucky	Robert Brawley	David Raines	Kraig Humbaugh
Louisiana	Lisa Ann Longfellow	Lisa Ann Longfellow	Raoult Ratard
Maine	Bob Woods	Jennah Godo	Kathleen F. Gensheimer
Maryland	Barbara Conrad	Glen Oltoff	David Blythe
Baltimore	Laura Herrera	Victoria Stovall	David Blythe
Massachusetts	Thomas Bertrand	Thomas Bertrand	Alfred DeMaria
Michigan	Mark Miller	Mark A. Miller	Corrine Miller
Minnesota	Julia Ashley	Julia Ashley	Ruth Lynfield
Mississippi	Craig Thompson	Craig Thompson	Lovetta Brown
Missouri	Herbert Michael	Vacant	Bao-Ping Zhu
Montana	Laurie Kops	Vacant	Todd A. Damrow
Nebraska	Phil Medina	Phil Medina	Thomas J. Safranek
Nevada	Richard Whitley	Bill Hill	Ishan Azzam
New Hampshire	Denise Rondeau	Drew Thomits	Jose Montero
New Jersey	Janet DeGraaf	Jerry Carolina	Eddy A. Bresnitz
New Mexico	Daryl Smith	Jaime Vega-Hernandez	C. Mack Sewell
New York	F. Bruce Coles	Dennis Murphy	Perry F. Smith
New York City	Susan Blank	Steve Rubin	Marcelle Layton
North Carolina	Evelyn M. Foust	Evelyn M. Foust	Jeffrey Engel
North Dakota	Kimberly Weis	Kimberly Weis	Kirby Kruger
Ohio	Barbara Bradley	Amy LaGessee	Forrest W. Smith
Oklahoma	Michael Harmon	Chang Lee	Kristy Bradley
Oregon	Vada Latin	Doug Harger	Melvin Kohn
Pennsylvania	Weston Ruhrig	Steve Kowalewski	Veronica Urdaneta
Philadelphia	Caroline Johnson	Vacant	Veronica Urdaneta
Rhode Island	Utpala Bandy	Michael Gosciminski	Utpala Bandy
South Carolina	Dorothy Waln (Acting)	Robert Ray	James J. Gibson
South Dakota	Laurie Gill	David Morgan	Lon Kightlinger
Tennessee	Jeaneece Seals	Robert Burke	Allen Craig
Texas	Felipe Rocha	Jim Lee	Vincent Fonseca
Utah	Jennifer Brown	Tim Lane	Robert T. Rolfs
Vermont	Daniel Daltry	Daniel Daltry	Cortland Lohff
Virginia	Kathryn Hafford	Kathryn Hafford (Acting)	Carl Armstrong
Washington	Larry Klopfenstein	Larry Klopfenstein	Marcia Goldoft
West Virginia	Loretta E. Haddy	Susan Hall	Loretta E. Haddy
Wisconsin	Sandra Breitborde	Anthony Wade	Jeffrey Davis
Wyoming	Brownen Anderson	Vacant	Tracy Murphy
American Samoa	Utoofili Asofaafeta Maga	Sarona Maae	Joseph Roth
Federated States of Micronesia	Nena S. Nena	Johnny Hebel	Nena S. Nena
Government of the Marshall Islands	Justina Langidrik	Zachraias Zachraias	James Hosfschneider
Guam	Josie O'Mallan	Bernadette Schumann	Robert L. Haddock
Puerto Rico	Greduvel Duran-Guzman	Trinidad Garcia	Enid Garcia
Republic of Palau	Victor Yano	Johana Ngiruchelbad	Julie Erb-Alvarez3
Virgin Islands	Darlene Carty	Taetia Phillips-Dorsett	Darlene Carty